Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: TGR0 >4%/month was associated with shorter progression-free survival (PFS) in patients (pts) treated with lanreotide in the CLARINET study. Impact of TGR0 in pts treated with other systemic therapies (ST) and with Ki67>10% is unknown.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Crona J
Authors: Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C,
Keywords: tumor growth rate, TGR, RECIST, Neuroendocrine Tumor,
Introduction: TGR (% change in tumour volume per month (%/m)) is postulated to be an early radiological biomarker to overcome limitations of RECIST in NETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Lamarca A
Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C,
Keywords: tumor growth rate, response, progression-free survival, follow-up, neuroendocrine tumor, prognosis, TGR, RECIST, radiology,
Introduction: The slow-growing character of neuroendocrine tumors (NET) makes it difficult to assess treatment impact on tumor growth.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Van Fraeyenhove F, Meireson N, Mattelaer C, De Droogh E, Galdermans D,
Keywords: non-functional lung neuroendocrine tumors, lanreotide, tumor growth, case-series,
Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Dromain C
Authors: Caplin M, Pavel M, Ruszniewski P, Liyanage N, Massien C,